Skip to main content
      RT @RichardPAConway: Yang et al. Incidence and risk factors for cutaneous lupus becoming SLE. 11.8% transitioned after 2

      Richard Conway RichardPAConway

      3 years 10 months ago
      Yang et al. Incidence and risk factors for cutaneous lupus becoming SLE. 11.8% transitioned after 20 years. Age<40 (HR 3.25), in first 10 years after skin lupus diagnosis, SCLE>DLE (HR 0.28)/others (HR 0.11) @rheumnow #ACR22 Abstr#0338 https://t.co/IxVS4mOveD https://t.co/3VeQ8WPQtU
      RT @uptoTate: Clinical pearl! Talk to your PsA pts about sleep. Abs 0387 shows circular relationship between sleep quali

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Clinical pearl! Talk to your PsA pts about sleep. Abs 0387 shows circular relationship between sleep quality, emotional disorders, and activity in these patients. Emotional factors more relevant than inflammatory factors on sleep quality. #ACR22 @RheumNow https://t.co/0p5hfNHM91 https://t.co/XrMTmsoMYR
      RT @RichardPAConway: Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance bigg

      Richard Conway RichardPAConway

      3 years 10 months ago
      Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance biggest contributors. Higher in relapsing 122.5 vs 98.9. BMI and neuropsych higher in relapsing. @rheumnow #ACR22 Abstr#0460 https://t.co/dSIt1xEOva https://t.co/2tAkgVEEeA
      RT @RichardPAConway: Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroi

      Richard Conway RichardPAConway

      3 years 10 months ago
      Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6
      RT @uptoTate: Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, pso

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, psoriasis, and health-related QoL. Top 3 pt-reported reasons for tx failure were pain, psoriasis and fatigue. Abs0393 #ACR22 @RheumNow https://t.co/F9RNI7EXcL https://t.co/7DcLaqUqnm
      RT @RichardPAConway: Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests wors

      Richard Conway RichardPAConway

      3 years 10 months ago
      Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests worse outcomes for Black patients relate to more severe disease at presentation rather than treatment failure @RheumNow #ACR22 Abstr#0521 https://t.co/xZtAt6Kw1f https://t.co/f0jG9jsgQ7
      RT @RichardPAConway: Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Sig

      Richard Conway RichardPAConway

      3 years 10 months ago
      Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Significantly lower Glucocorticoid toxicity index -29.5 at 12 months -20 at 24 months. Not convinced until I see stronger data! @rheumnow #ACR22 Abstr#0128 https://t.co/20K4dKXE7R https://t.co/X4kJgCqhAE
      RT @RichardPAConway: Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men th

      Richard Conway RichardPAConway

      3 years 10 months ago
      Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men than women with AxSpA. Our current tools may be inadequate to fully evaluate women with AxSpA @rheumnow #ACR22 Abstr#0406 https://t.co/duHqO0DXh3 https://t.co/yRcFiNpujT
      RT @KDAO2011: Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt
      RT @doctorRBC: Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo. BMI <25: more AE and SAE Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD
      RT @doctorRBC: Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA a

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK
      RT @AurelieRheumo: Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, th

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis. Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%. https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7
      RT @AurelieRheumo: MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA.

      6000+ pts received UPA 40-50% w/ &gt; or = 2 BL

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA. 6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors. 41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group. Overlapping confidence intervals w/ADA & MTX. https://t.co/7xtZlDIkVu Abs#0510 #ACR22 @Rheumnow https://t.co/reywXk5Z0Z
      RT @JulianSegan: RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n

      Julian Segan JulianSegan

      3 years 10 months ago
      RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n @RheumNow #ACR22 #Plenary
      RT @JulianSegan: GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD an

      Julian Segan JulianSegan

      3 years 10 months ago
      GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD and Sjogrens. @RheumNow #ACR22 #Pearls https://t.co/Gw6OF4H2w2
      ×